963 Stock Overview
Huadong Medicine Co., Ltd produces and sells various pharmaceutical products in China.
Huadong Medicine Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥42.40|
|52 Week High||CN¥49.00|
|52 Week Low||CN¥27.75|
|1 Month Change||-7.81%|
|3 Month Change||23.44%|
|1 Year Change||11.64%|
|3 Year Change||49.82%|
|5 Year Change||55.57%|
|Change since IPO||986.48%|
Recent News & Updates
|963||CN Healthcare||CN Market|
Return vs Industry: 000963 exceeded the CN Healthcare industry which returned -21.9% over the past year.
Return vs Market: 000963 exceeded the CN Market which returned -10.1% over the past year.
|963 Average Weekly Movement||6.3%|
|Healthcare Industry Average Movement||5.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in CN Market||9.1%|
|10% least volatile stocks in CN Market||3.9%|
Stable Share Price: 000963 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 000963's weekly volatility (6%) has been stable over the past year.
About the Company
Huadong Medicine Co., Ltd produces and sells various pharmaceutical products in China. It offers Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, medical cosmetology, and antibiotic drugs, as well as medical equipment. The company’s products include gastrointestinal agents, APIs, and other products.
Huadong Medicine Fundamentals Summary
|963 fundamental statistics|
Is 963 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|963 income statement (TTM)|
|Cost of Revenue||CN¥24.63b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.34|
|Net Profit Margin||6.58%|
How did 963 perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Is 963 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 963?
Other financial metrics that can be useful for relative valuation.
|What is 963's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 963's PE Ratio compare to its peers?
|963 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
601607 Shanghai Pharmaceuticals Holding
600511 China National Medicines
600998 Jointown Pharmaceutical Group
301015 Qingdao Baheal Medical
000963 Huadong Medicine
Price-To-Earnings vs Peers: 000963 is expensive based on its Price-To-Earnings Ratio (31.7x) compared to the peer average (16.9x).
Price to Earnings Ratio vs Industry
How does 963's PE Ratio compare vs other companies in the CN Healthcare Industry?
Price-To-Earnings vs Industry: 000963 is good value based on its Price-To-Earnings Ratio (31.7x) compared to the CN Healthcare industry average (32.2x)
Price to Earnings Ratio vs Fair Ratio
What is 963's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||31.7x|
|Fair PE Ratio||32.2x|
Price-To-Earnings vs Fair Ratio: 000963 is good value based on its Price-To-Earnings Ratio (31.7x) compared to the estimated Fair Price-To-Earnings Ratio (32.2x).
Share Price vs Fair Value
What is the Fair Price of 963 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 000963 (CN¥42.4) is trading above our estimate of fair value (CN¥9.6)
Significantly Below Fair Value: 000963 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Huadong Medicine forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000963's forecast earnings growth (21.5% per year) is above the savings rate (3.2%).
Earnings vs Market: 000963's earnings (21.5% per year) are forecast to grow slower than the CN market (24.5% per year).
High Growth Earnings: 000963's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 000963's revenue (10.6% per year) is forecast to grow slower than the CN market (17.7% per year).
High Growth Revenue: 000963's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000963's Return on Equity is forecast to be low in 3 years time (15.8%).
Discover growth companies
How has Huadong Medicine performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 000963 has high quality earnings.
Growing Profit Margin: 000963's current net profit margins (6.6%) are lower than last year (7%).
Past Earnings Growth Analysis
Earnings Trend: 000963's earnings have grown by 5.9% per year over the past 5 years.
Accelerating Growth: 000963's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000963 had negative earnings growth (-2%) over the past year, making it difficult to compare to the Healthcare industry average (2.5%).
Return on Equity
High ROE: 000963's Return on Equity (13.2%) is considered low.
Discover strong past performing companies
How is Huadong Medicine's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 000963's short term assets (CN¥16.6B) exceed its short term liabilities (CN¥9.1B).
Long Term Liabilities: 000963's short term assets (CN¥16.6B) exceed its long term liabilities (CN¥2.0B).
Debt to Equity History and Analysis
Debt Level: 000963 has more cash than its total debt.
Reducing Debt: 000963's debt to equity ratio has reduced from 19.1% to 14.4% over the past 5 years.
Debt Coverage: 000963's debt is well covered by operating cash flow (67.1%).
Interest Coverage: 000963 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Huadong Medicine current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 000963's dividend (0.68%) is higher than the bottom 25% of dividend payers in the CN market (0.45%).
High Dividend: 000963's dividend (0.68%) is low compared to the top 25% of dividend payers in the CN market (1.88%).
Stability and Growth of Payments
Stable Dividend: 000963 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 000963's dividend payments have increased, but the company has only paid a dividend for 8 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (21.7%), 000963's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (72.9%), 000963's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Huadong Medicine has no CEO, or we have no data on them.
Experienced Management: 000963's management team is considered experienced (3.2 years average tenure).
Experienced Board: 000963's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Huadong Medicine Co., Ltd's employee growth, exchange listings and data sources
- Name: Huadong Medicine Co., Ltd
- Ticker: 963
- Exchange: SZSE
- Founded: 1993
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: CN¥74.192b
- Shares outstanding: 1.75b
- Website: https://www.eastchinapharm.com
Number of Employees
- Huadong Medicine Co., Ltd
- No. 866 Moganshan Road
- Zhejiang Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.